Interferon regulatory factor3 and its alternative splicing isoforms in
tumorLiu Zhonghui, Sun Dan, Liu Xinmin.

doi:10.3760/cma.j.issn.1673422X.2017.03.010

Abstract

Abstract: As a member of interferon regulatory factor family (IRF), IRF3 plays an important role in triggering the expression of type Ⅰ interferons and downstream interferonstimulated genes, contributing to many biological process. Researches have found that it plays an antioncogene role in inhibiting tumor proliferation and migration, inducing cell apoptosis. The mechanism involves in tumor immunity and inflammatory reaction, apoptosis and epithelial mesenchymal transition. The alternative splicing isoforms of IRF3 act as negative modulators of IRF3 and affect tumor development progress. The recent signaling pathways and pathogenesis researches provide new ideas for early diagnosis and treatment of cancer.

Key words: Interferon regulatory factor3, Spliceosomes, Neoplasms

Liu Zhonghui, Sun Dan, Liu Xinmin. Interferon regulatory factor3 and its alternative splicing isoforms in tumorLiu Zhonghui, Sun Dan, Liu Xinmin.[J]. Journal of International Oncology, 2017, 44(3): 196-200.

References

［1］ Marsili G, Perrotti E, Remoli AL, et al. IFN regulatory factors and antiviral innate immunity: how viruses can get better［J］. J Interferon Cytokine Res, 2016, 36(7): 414-432. DOI: 10.1089/jir.2016.0002. ［2］ Yanai H, Negishi H, Taniguchi T. The IRF family of transcription factors: inception, impact and implications in oncogenesis［J］. Oncoimmunology, 2012, 1(8): 1376-1386. DOI: 10.4161/onci.22475. ［3］ Tarassishin L, Bauman A, Suh HS, et al. Antiviral and antiinflammatory mechanisms of the innate immune transcription factor interferon regulatory factor 3: relevance to human CNS diseases［J］. J Neuroimmune Pharmacol, 2013, 8(1): 132-144. DOI: 10.1007/s114810129360 5. ［4］ Ikushima H, Negishi H, Taniguchi T. The IRF family transcription factors at the interface of innate and adaptive immune responses［J］. Cold Spring Harb Symp Quant Biol, 2013, 78(78): 105-116. DOI: 10.1101/sqb.2013.78.020321. ［5］ Zhao GN, Jiang DS, Li H. Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease［J］. Biochim Biophys Acta, 2015, 1852(2): 365-378. DOI: 10.1016/j.bbadis.2014.04.030. ［6］ Grandvaux N, Guan X, Yoboua F, et al. Sustained activation of interferon regulatory factor 3 during infection by paramyxoviruses requires MDA5［J］. J Innate Immun, 2014, 6(5): 650-662. DOI: 10.1159/000360764. ［7］ Andzinski L, Spanier J, Kasnitz N, et al. Growing tumors induce a local STING dependent Type Ⅰ IFN response in dendritic cells［J］. Int J Cancer, 2016, 139(6): 1350-1357. DOI: 10.1002/ijc.30159. ［8］ SterneWeiler T, Sanford JR. Exon identity crisis: diseasecausing mutations that disrupt the splicing code［J］. Genome Biol, 2014, 15(1): 201. DOI: 10.1186/gb4150. ［9］ Wang ET, Sandberg R, Luo S, et al. Alternative isoform regulation in human tissue transcriptomes［J］. Nature, 2008, 456(7221): 470-476. DOI: 10.1038/nature07509. ［10］ Wiszomirska H, PiekiekoWitkowska A, Nauman A. Disturbances of alternative splicing in cancer［J］. Postepy Biochem, 2011, 57(3): 257-265. ［11］ Abou Faycal C, Gazzeri S, Eymin B. RNA splicing, cell signaling, and response to therapies［J］. Curr Opin Oncol, 2016, 28(1): 58-64. DOI: 10.1097/CCO.0000000000000254. ［12］ BiselliChicote PM, Oliveira AR, Pavarino EC, et al. VEGF gene alternative splicing: pro and antiangiogenic isoforms in cancer［J］. J Cancer Res Clin Oncol, 2012, 138(3): 363-370. DOI: 10.1007/s0043201110732. ［13］ Anczuków O, Krainer AR. Splicingfactor alterations in cancers［J］ . RNA, 2016, 22(9): 1285-1301. DOI: 10.1261/rna.057919.116. ［14］ Li Y, Hu X, Song Y, et al. Identification of novel alternative splicing variants of interferon regulatory factor 3［J］. Biochim Biophys Acta, 2011, 1809(3): 166-175. DOI: 10.1016/j.bbagrm.2011.01.006. ［15］ Tiwari N, Gheldof A, Tatari M, et al. EMT as the ultimate survival mechanism of cancer cells［J］. Semin Cancer Biol, 2012, 22(3): 194-207. DOI: 10.1016/j.semcancer.2012.02.013. ［16］ Nieto MA, Huang RY, Jackson RA, et al. EMT: 2016［J］. Cell, 2016, 166(1): 21-45. DOI: 10.1016/j.cell.2016.06.028. ［17］ Gao D, Vahdat LT, Wong S, et al. Microenvironmental regulation of epithelialmesenchymal transitions in cancer［J］. Cancer Res, 2012, 72 (19): 4883-4889. DOI: 10.1158/00085472.CAN121223. ［18］ Xu P, BaileyBucktrout S, Xi Y, et al. Innate antiviral host defense attenuates TGFβ function through IRF3mediated suppression of Smad signaling［J］. Mol Cell, 2014, 56(6): 723-737. DOI: 10.1016/j.molcel.2014.11.027. ［19］ Zhu S, Li HB, Flavell RA. Resemble and inhibit: when RLR meets TGF beta［J］. Mol Cell, 2014, 56(6): 719-720. DOI: 10.1016/j.molcel.2014.12.010. ［20］ Pythoud C, Rothenberger S, MartínezSobrido L, et al. Lymphocytic choriomeningitis virus differentially affects the virusinduced type Ⅰ interferon response and mitochondrial apoptosis mediated by RIGⅠ/MAVS［J ］. J Virol, 2015, 89(12): 6240-6250. DOI: 10.1128/JVI.0061015. ［21］ Yuan MM, Xu YY, Chen L, et al. TLR3 expression correlates with apoptosis, proliferation and angiogenesis in hepatocellular carcinoma and predicts prognosis［J］. BMC Cancer, 2015, 15: 245. DOI: 10.1186/s1288501512625. ［22］ Gambara G, Desideri M, Stoppacciaro A, et al. TLR3 engagement induces IRF3dependent apoptosis in androgensensitive prostate cancer cells and inhibits tumour growth in vivo［J］. J Cell Mol Med, 2015, 19(2): 327-339. DOI: 10.1111/jcmm.12379. ［23］ Mantovani A. Molecular pathways linking inflammation and cancer［J］ . Curr Mol Med, 2010, 10(4): 369-373. ［24］ Mougiakakos D, Choudhury A, Lladser A, et al. Regulatory T cells in cancer［J］. Adv Cancer Res, 2010, 107: 57-117. DOI: 10.1016/S0065230X (10)07003X. ［25］ Guo R, Li Y, Ning J, et al. HnRNP A1/A2 and SF2/ASF regulate alternative splicing of interferon regulatory factor3 and affect immunomodulatory functions in human nonsmall cell lung cancer cells［J］. PLoS One, 2013, 8(4): e62729. DOI: 10.1371/journal.pone.0062729. ［26］ Szabo A, Fekete T, Koncz G, et al. RIGⅠ inhibits the MAPKdependent proliferation of BRAF mutant melanoma cells via MKP1［J］ . Cell Signal, 2016, 28(5): 335-347. DOI: 10.1016/j.cellsig.2016.01.012. ［27］ Duewell P, Beller E, Kirchleitner SV, et al. Targeted activation of melanoma differentiationassociated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma［J］. Oncoimmunology, 2015, 4(10): e1029698. DOI: 10.1080/2162402X.2015.1029698. ［28］ Liu B, Wang X, Chen TZ, et al. Polarization of M1 tumor associated macrophage promoted by the activation of TLR3 signal pathway［J］. Asian Pac J Trop Med, 2016, 9(5): 484-488. DOI: 10.1016/j.apjtm.2016.03.019. ［29］ Liu Y, Li T, Xu Y, et al. Effects of TLR4 gene silencing on the proliferation and apotosis of hepatocarcinoma HEPG2 cells［J］. Oncol Lett, 2016, 11(5): 3054-3060. ［30］ Muvaffak A, Pan Q, Yan H, et al. Evaluating TBK1 as a therapeutic target in cancers with activated IRF3［J］. Mol Cancer Res, 2014, 12(7): 1055-1066. DOI: 10.1158/15417786.MCR130642.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.

Interferon regulatory factor3 and its alternative splicing isoforms in tumorLiu Zhonghui, Sun Dan, Liu Xinmin.

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments